Wendell Wierenga - 01 Sep 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Director
Issuer ticker: CRNX
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Sep 2026, 17:02:38 UTC
Prior SEC filing: 16 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Tobin Schilke, as attorney-in-fact

Key filing fact

Wendell Wierenga filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 01 Sep 2026.

Key facts

This page summarizes Wendell Wierenga's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
10 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 01 Sep 2026, 17:02.

Change

Previous filing in this sequence was filed on 16 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001239956 Primary reporting owner

WIERENGA WENDELL

Relationship: Director
Address: C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature: /s/ Tobin Schilke, as attorney-in-fact
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -116,146
Change %: -95%
Price: $85.00^*
Shares after: 5,925
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

CRNX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -5,925
Change %: -100%
Price: $85.00^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -12,500
Change %: -100%
Price: $61.76^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $23.24
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -12,500
Change %: -100%
Price: $61.77^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $23.23
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -17,500
Change %: -100%
Price: $64.77^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $20.23
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -17,500
Change %: -100%
Price: $66.71^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $18.29
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -17,500
Change %: -100%
Price: $64.68^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $20.32
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -12,500
Change %: -100%
Price: $40.29^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $44.71
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,350
Change %: -100%
Price: $52.67^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,350
Exercise price: $32.33
Footnotes: F3, F4

CRNX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -9,730
Change %: -100%
Price: $49.13^*
Shares after: 0
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,730
Exercise price: $35.87
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Wendell Wierenga is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").

Footnote F2

The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.

Footnote F3

The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

Footnote F4

The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.